Sponsored
Krystal Haynes, Senior Director of Business Development, ICS, at Cencora, outlines the challenges facing cell and gene therapy manufacturers as they attempt to move products from clinical development to commercial availability.
Krystal Haynes, Senior Director of Business Development, ICS
Advertisement
Articles by Krystal Haynes, Senior Director of Business Development, ICS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
UCB Enters $2.2 Billion Agreement to Acquire Candid Therapeutics
2
Pharmaceutical Executive Daily: UCB to Acquire Candid Therapeutics
3
Scaling Innovation Without Losing Executional Rigor: Q&A with Mark Thierer
4
How a Shifting Landscape is Making Affordable DTP At Scale a Reality
5